Catheter-Directed Low-Dose Tissue Plasminogen Activator for Treatment of Right Atrial Thrombus Caused by a Central Venous Catheter

Gabriela M. Orgeron, Jessica L. Pollard, Paria Pourmalek, Peter J. Sloane

Research output: Contribution to journalArticle

Abstract

Catheter-related atrial thrombosis is a potentially deadly complication of central venous catheters. Options for treatment include surgical thrombectomy, systemic anticoagulation, and systemic thrombolysis, but the optimal method of treatment remains unknown. We describe a 48-year-old woman with a large right atrial thrombus who was successfully treated with localized recombinant tissue plasminogen activator (tPA). She was treated with an 18-hour infusion of localized low-dose tPA administered through her central venous catheter. The dimensions of the thrombus decreased from 30 × 16 × 22 mm to 10 × 8 × 5 mm after treatment with tPA, corresponding to an associated 96% reduction in thrombus volume. No major bleeding complications were observed. Catheter-directed thrombolysis provides the theoretical advantage of a decreased rate of major bleeding by reducing the exposure to and duration of high-dose systemic thrombolytic therapy. To our knowledge, this is the second case report describing the use of this novel therapy. Although no guidelines for the treatment of atrial thrombosis or consensus on the optimal regimen for catheter-directed thrombolysis (and intensity of concomitant anticoagulation) exist, we believe that this intervention may be a well-tolerated alternative to systemic thrombolysis and surgery in certain patients.

Original languageEnglish (US)
Pages (from-to)e153-e158
JournalPharmacotherapy
Volume35
Issue number10
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Central Venous Catheters
Tissue Plasminogen Activator
Thrombosis
Catheters
Hemorrhage
Therapeutics
Thrombectomy
Thrombolytic Therapy
Guidelines

Keywords

  • atrial thrombus
  • catheter-directed
  • tissue plasminogen activator

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Catheter-Directed Low-Dose Tissue Plasminogen Activator for Treatment of Right Atrial Thrombus Caused by a Central Venous Catheter. / Orgeron, Gabriela M.; Pollard, Jessica L.; Pourmalek, Paria; Sloane, Peter J.

In: Pharmacotherapy, Vol. 35, No. 10, 01.10.2015, p. e153-e158.

Research output: Contribution to journalArticle

Orgeron, Gabriela M. ; Pollard, Jessica L. ; Pourmalek, Paria ; Sloane, Peter J. / Catheter-Directed Low-Dose Tissue Plasminogen Activator for Treatment of Right Atrial Thrombus Caused by a Central Venous Catheter. In: Pharmacotherapy. 2015 ; Vol. 35, No. 10. pp. e153-e158.
@article{6e0b53da3a59429c904a0af4e55ae70d,
title = "Catheter-Directed Low-Dose Tissue Plasminogen Activator for Treatment of Right Atrial Thrombus Caused by a Central Venous Catheter",
abstract = "Catheter-related atrial thrombosis is a potentially deadly complication of central venous catheters. Options for treatment include surgical thrombectomy, systemic anticoagulation, and systemic thrombolysis, but the optimal method of treatment remains unknown. We describe a 48-year-old woman with a large right atrial thrombus who was successfully treated with localized recombinant tissue plasminogen activator (tPA). She was treated with an 18-hour infusion of localized low-dose tPA administered through her central venous catheter. The dimensions of the thrombus decreased from 30 × 16 × 22 mm to 10 × 8 × 5 mm after treatment with tPA, corresponding to an associated 96{\%} reduction in thrombus volume. No major bleeding complications were observed. Catheter-directed thrombolysis provides the theoretical advantage of a decreased rate of major bleeding by reducing the exposure to and duration of high-dose systemic thrombolytic therapy. To our knowledge, this is the second case report describing the use of this novel therapy. Although no guidelines for the treatment of atrial thrombosis or consensus on the optimal regimen for catheter-directed thrombolysis (and intensity of concomitant anticoagulation) exist, we believe that this intervention may be a well-tolerated alternative to systemic thrombolysis and surgery in certain patients.",
keywords = "atrial thrombus, catheter-directed, tissue plasminogen activator",
author = "Orgeron, {Gabriela M.} and Pollard, {Jessica L.} and Paria Pourmalek and Sloane, {Peter J.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/phar.1645",
language = "English (US)",
volume = "35",
pages = "e153--e158",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Catheter-Directed Low-Dose Tissue Plasminogen Activator for Treatment of Right Atrial Thrombus Caused by a Central Venous Catheter

AU - Orgeron, Gabriela M.

AU - Pollard, Jessica L.

AU - Pourmalek, Paria

AU - Sloane, Peter J.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Catheter-related atrial thrombosis is a potentially deadly complication of central venous catheters. Options for treatment include surgical thrombectomy, systemic anticoagulation, and systemic thrombolysis, but the optimal method of treatment remains unknown. We describe a 48-year-old woman with a large right atrial thrombus who was successfully treated with localized recombinant tissue plasminogen activator (tPA). She was treated with an 18-hour infusion of localized low-dose tPA administered through her central venous catheter. The dimensions of the thrombus decreased from 30 × 16 × 22 mm to 10 × 8 × 5 mm after treatment with tPA, corresponding to an associated 96% reduction in thrombus volume. No major bleeding complications were observed. Catheter-directed thrombolysis provides the theoretical advantage of a decreased rate of major bleeding by reducing the exposure to and duration of high-dose systemic thrombolytic therapy. To our knowledge, this is the second case report describing the use of this novel therapy. Although no guidelines for the treatment of atrial thrombosis or consensus on the optimal regimen for catheter-directed thrombolysis (and intensity of concomitant anticoagulation) exist, we believe that this intervention may be a well-tolerated alternative to systemic thrombolysis and surgery in certain patients.

AB - Catheter-related atrial thrombosis is a potentially deadly complication of central venous catheters. Options for treatment include surgical thrombectomy, systemic anticoagulation, and systemic thrombolysis, but the optimal method of treatment remains unknown. We describe a 48-year-old woman with a large right atrial thrombus who was successfully treated with localized recombinant tissue plasminogen activator (tPA). She was treated with an 18-hour infusion of localized low-dose tPA administered through her central venous catheter. The dimensions of the thrombus decreased from 30 × 16 × 22 mm to 10 × 8 × 5 mm after treatment with tPA, corresponding to an associated 96% reduction in thrombus volume. No major bleeding complications were observed. Catheter-directed thrombolysis provides the theoretical advantage of a decreased rate of major bleeding by reducing the exposure to and duration of high-dose systemic thrombolytic therapy. To our knowledge, this is the second case report describing the use of this novel therapy. Although no guidelines for the treatment of atrial thrombosis or consensus on the optimal regimen for catheter-directed thrombolysis (and intensity of concomitant anticoagulation) exist, we believe that this intervention may be a well-tolerated alternative to systemic thrombolysis and surgery in certain patients.

KW - atrial thrombus

KW - catheter-directed

KW - tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=84945119108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945119108&partnerID=8YFLogxK

U2 - 10.1002/phar.1645

DO - 10.1002/phar.1645

M3 - Article

C2 - 26497485

AN - SCOPUS:84945119108

VL - 35

SP - e153-e158

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 10

ER -